Bumetanide (Burinex) tab 1 mg: Supply issue
PHARMAC have been made aware of a supply issue with bumetanide (Burinex) tab 1 mg.
The supplier has sourced an alternative brand so patients can continue to access treatment. PHARMAC has already listed the brand in the Pharmaceutical Schedule. It is the same alternative brand that was supplied in May 2020.
The alternative brand is not registered in New Zealand so will need to be supplied under Section 29 of the Medicines Act.
We are advised that supply of the registered brand, Burinex, will be available early in the New Year.
What section 29 means
Section 29 allows for medicines that are not Medsafe approved to be supplied to people. The medicine must be prescribed by someone registered with the Medical Council of New Zealand – e.g., doctors.
We know supplying a medicine under section 29 is not ideal. In this case, however, the alternative would be for patients to have no bumetanide 1 mg tablets.
We apologise for any inconvenience this causes.